Research programme: anti-inflammatory therapeutics - Omeros Corporation

Drug Profile

Research programme: anti-inflammatory therapeutics - Omeros Corporation

Alternative Names: anti MASP-3 antibody - Omeros Corporation; anti-MASP-2 monoclonal antibody - Omeros Corporation; MASP-2 therapeutics - Omeros Corporation; MASP-3 therapeutics - Omeros Corporation; OMS 906

Latest Information Update: 09 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Omeros Corporation
  • Class Anti-inflammatories; Eye disorder therapies; Monoclonal antibodies; Small molecules
  • Mechanism of Action Mannose binding protein associated serine protease inhibitors; MASP2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration; Haemolytic uraemic syndrome; Inflammation; Myocardial reperfusion injury; Paroxysmal nocturnal haemoglobinuria; Reperfusion injury; Stroke

Most Recent Events

  • 10 May 2018 Omeros Corporation plans a clinical trial for MASP-2 inhibitors in late 2019
  • 10 May 2018 Omeros Corporation plans a clinical trial for OMS 906 in late 2019
  • 09 Jan 2018 Preclinical development is ongoing for Age-related macular degeneration, Haemolytic uraemic syndrome, Inflammation, Myocardial reperfusion injury, Paroxysmal nocturnal haemoglobinuria, Reperfusion injury and Stroke (9230403; Omeros Corporation Pipeline and 2016 Annual Report)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top